HLHR13: Adcetris® (Brentuximab Vedotin) Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL) Diseases: High risk Hodgkin Lymphoma


Leukemias / Lymphomas : High risk Hodgkin lymphoma


Hodgkin lymphoma is a cancer of the lymph system (a part of the body’s immune system). The lymph system is made up of tissue throughout the body that makes and stores infection-fighting cells. The term “risk” refers to the chance of the cancer coming back after treatment.

In this study, a commonly used multi-drug chemotherapy (anti-cancer) regimen for Hodgkin lymphoma will be used called “OEPA/COPDac”, except that a new drug called “brentuximab vedotin (also called Adcetris®)” will be substituted for one of the usual drugs called vincristine, making this treatment “AEPA/CAPDac”. Brentuximab vedotin is a drug known as an “antibody-drug conjugate (ADC)”. It is made up of 2 parts. The first part is a type of antibody (a man-made version of an immune system protein) that finds and attaches to the surface of most lymphoma cells. The second part is a chemotherapy (anti-cancer) drug that stops the cancer cell from dividing, and kills the cancer cell.

This study has 2 parts:

1. Treatment phase: treatment with chemotherapy and in some participants, radiation therapy. Radiation will start within 2-3 weeks after completing all CAPDac chemotherapy and blood counts have recovered. Radiation treatments will be given to lymph node groups that did not go into remission after the first 2 cycles of AEPA chemotherapy.

2. Follow-up phase: monitor you long-term to look for signs Hodgkin lymphoma has returned and for late effects of treatment


Eligibility criteria:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Monika Metzger, MD, MS
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.